1. Psychiatric Symptoms in Patients Receiving Dolutegravir.
- Author
-
Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, and Curtis L
- Subjects
- Anxiety psychology, Clinical Trials, Phase III as Topic, Depression psychology, HIV Integrase Inhibitors administration & dosage, Heterocyclic Compounds, 3-Ring administration & dosage, Humans, Male, Oxazines, Piperazines, Psychoses, Substance-Induced, Pyridones, Randomized Controlled Trials as Topic, Sleep Initiation and Maintenance Disorders psychology, Suicidal Ideation, Treatment Outcome, Young Adult, Anxiety chemically induced, Depression chemically induced, HIV Infections drug therapy, HIV Integrase Inhibitors adverse effects, Heterocyclic Compounds, 3-Ring adverse effects, Sleep Initiation and Maintenance Disorders chemically induced
- Abstract
Introduction: Psychiatric symptoms (PSs) are reported to occur frequently in people living with HIV and may be associated with specific antiretrovirals. We analyzed PSs observed with dolutegravir (DTG) and other frequently prescribed anchor drugs., Methods: Selected PSs (insomnia, anxiety, depression, and suicidality) occurring in HIV-positive patients during DTG treatment across 5 randomized clinical trials (3 double-blind), in the Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort, and among cases spontaneously reported to ViiV Healthcare were analyzed., Results: In clinical trials, PSs were reported at low and similar rates in patients receiving DTG or comparators [atazanavir, darunavir, efavirenz, or raltegravir (RAL)]. Insomnia was most commonly reported. The highest rates were observed in SINGLE (DTG 17%, efavirenz 12%), with consistently lower rates in the other trials (DTG: 3%-8% versus comparator: 3%-7%). More efavirenz-treated patients withdrew because of PSs than patients treated with other anchor drugs. In OPERA, history of PSs at baseline was lowest in efavirenz-treated patients compared with patients treated with DTG, RAL, or darunavir. Despite baseline differences, prevalence and incidence during treatment were similar across the 4 anchor drugs. Withdrawal rates for PSs were lowest for DTG (0%-0.6%) and highest for RAL (0%-2.5%). Spontaneously reported events were similar in nature to clinical trial data., Conclusions: Analysis of 3 different data sources shows that, similar to other frequently prescribed anchor drugs to treat HIV infection, PSs are also reported in DTG-treated patients. These events are reported with low frequency and rarely necessitate DTG discontinuation.
- Published
- 2017
- Full Text
- View/download PDF